The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II
Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is
Blog
Why the ATU needs to evolve with the brand
Steve Wakefield leads the Quantitative Center of Excellence at Fulcrum Research, part of SAI. With more than 25 years of
Stability and Flexibility: Transforming your ATU tracker into an adaptive learning system
Your market changes – your ATU should change, too At Fulcrum Research, we transform your ATU into an adaptive learning
Five Biotech Milestones – Lab to Success
Developing a molecule from lab to patients requires more than 1,000 decisions, made right and at the right time. However, the
Closing the AI Perception Gap
A perspective from Fulcrum Research Group A recent article from bi.team explored an idea that immediately resonated with us: people tend to believe AI
Why Patient Journey Research Shouldn’t End with a PowerPoint
Every pharmaceutical company conducts research to better understand patients. Then, more often than not, those insights live on a shared
Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective & Anti-Inflammatory Strategy
Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and
The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.
Welcome to a special edition of IDEA Collider’s “Deep Medicine” series. In this episode, host Alex Gray sits down with
The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning
Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior
The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution
Welcome to IDEA Collider. In this episode, host Dr. Alex Gray is joined by IDEA Pharma colleagues David Radwaner and